DnB Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$412K	Buy	18,523 +3,821	+26%	+$91.3K	﹤0.01%	831
2025 Q4	$393K	Buy	14,702 +1,525	+12%	+$36.4K	﹤0.01%	687
2025 Q3	$281K	Buy	13,177 +2,258	+21%	+$53.4K	﹤0.01%	697
2025 Q2	$236K	Sell	10,919 -4,692	-30%	-$87.2K	﹤0.01%	688
2025 Q1	$259K	Buy	15,611 +1,409	+10%	+$25.6K	﹤0.01%	699
2024 Q4	$261K	Buy	14,202 +3,964	+39%	+$64K	﹤0.01%	696
2024 Q3	$157K	Buy	10,238 +113	+1%	+$1.89K	﹤0.01%	698
2024 Q2	$165K	Buy	+10,125	New	+$163K	﹤0.01%	697
2023 Q3	–	Sell	-12,141	Closed	-$291K	–	659
2023 Q2	$291K	Buy	+12,141	New	+$270K	﹤0.01%	650
2022 Q3	–	Sell	-46,171	Closed	-$651K	–	647
2022 Q2	$651K	Sell	46,171 -21,471	-32%	-$401K	﹤0.01%	617
2022 Q1	$1.64M	Sell	67,642 -14,440	-18%	-$349K	0.01%	570
2021 Q4	$1.92M	Sell	82,082 -8,758	-10%	-$176K	0.01%	569
2021 Q3	$1.51M	Sell	90,840 -2,119	-2%	-$40.8K	0.01%	575
2021 Q2	$2.27M	Buy	92,959 +483	+0.5%	+$10.9K	0.02%	520
2021 Q1	$2.39M	Buy	92,476 +37,378	+68%	+$1.65M	0.02%	500
2020 Q4	$2.95M	Buy	55,098 +32,556	+144%	+$1.62M	0.03%	381
2020 Q3	$930K	Buy	+22,542	New	+$973K	0.01%	531